Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease Data from the Bezafibrate Infarction Prevention (BIP) Study by Haim, Moti et al.
Soluble Intercellular Adhesion Molecule-1 and Long-
Term Risk of Acute Coronary Events in Patients
With Chronic Coronary Heart Disease
Data From the Bezafibrate Infarction Prevention (BIP) Study
Moti Haim, MD,*† David Tanne, MD,*‡§ Valentina Boyko, MSC,*‡ Tamar Reshef, MSC,*†
Uri Goldbourt, PHD,*‡ Jonathan Leor, MD,*‡ Yoseph A. Mekori, MD,*† Solomon Behar, MD*‡
Tel-Aviv, Kfar-Saba and Tel-Hashomer, Israel
OBJECTIVES The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1)
level as a predictor of future acute coronary events in patients with chronic coronary heart
disease (CHD).
BACKGROUND Increased sICAM-1 concentration has been shown to be associated with the incidence of
CHD in healthy persons. Its significance in patients with CHD has been scarcely
investigated.
METHODS We designed a prospective, nested case-control study. Sera were collected from patients with
CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in
reducing coronary events. We measured baseline sICAM-1 concentration in the sera of
patients who developed subsequent cardiovascular events (cases: n  136) during follow-up
(mean: 6.2 years) and in age- and gender-matched controls (without events: n  136).
RESULTS Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls
(375 vs. 350 ng/ml; p  0.05). Each 100 ng/ml increase in sICAM-1 concentration was
associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of
coronary events. Soluble ICAM-1 concentration in the highest quartile (394 ng/ml) was
associated with significantly higher odds of coronary events (compared with the lowest
quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding
fibrinogen and total white blood cell count to the multivariate model, the relative odds were
2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively.
CONCLUSIONS Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future
coronary events independent of other traditional risk factors. (J Am Coll Cardiol 2002;39:
1133–8) © 2002 by the American College of Cardiology Foundation
Inflammation, whereby adhesion molecules play an impor-
tant role, has been implicated in the pathogenesis of
atherosclerosis (1). Cellular adhesion molecules mediate the
margination, adhesion and transendothelial migration of
circulating mononuclear cells from the blood stream to the
extravascular compartment and have an important role in
the progression of atherosclerotic plaque (1,2). In addition,
adhesion molecules and various other cytokines recruit and
activate mononuclear cells to release matrix metalloprotein-
ases, promoting plaque rupture and the initiation of acute
coronary syndromes (1,3–5).
Various inflammatory markers have been proposed to
assist in the prediction of subsequent coronary events among
healthy persons (6 – 8). Soluble intercellular adhesion
molecule-1 (sICAM-1) and other adhesion molecules have
been found to be associated with subsequent incidence of
coronary heart disease (CHD) among healthy men and
women in some studies (7,9–11) but not in others (12).
In some cross-sectional studies among patients with
CHD, sICAM-1 was a better predictor for the presence of
atherosclerosis and CHD than other adhesion molecules
(13). However, other studies did not find elevated levels of
sICAM-1 in patients with stable or unstable CHD (14,15).
One small study among CHD patients found higher base-
line serum levels of several adhesion molecules in patients
who subsequently had cardiovascular events than in patients
who did not develop cardiovascular events during follow-up
(16). However, that study was too small to account for
confounding variables.
In the present study, we evaluated the association be-
tween sICAM-1 levels and risk of future acute coronary
events over a long follow-up time in patients with chronic
stable CHD.
METHODS
Study sample. The sample for the present study was
selected from the Bezafibrate Infarction Prevention (BIP)
study. This was a placebo-controlled, randomized, second-
ary prevention trial that evaluated the efficacy of the lipid-
lowering drug bezafibrate in reducing death and non-fatal
myocardial infarction (MI) in patients (n  3,090) with
CHD (17).
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In the BIP study, CHD was defined as either a history of
MI 6 months, but 5 years, before enrollment to the
study or a history of angina pectoris confirmed by a positive
coronary angiography, by nuclear scintigraphy or by a
positive exercise test (17). Primary end points of the study
were fatal MI, non-fatal MI or sudden death. These end
points were reviewed and confirmed by an independent
critical event committee whose members were blinded to
the treatment assignment of study participants. Mean
length of follow-up was 6.2 years (range: 4.7 to 7.6 years).
For the purpose of the present study, we planned a
prospective, nested, case-control study. Case subjects (n 
134) were randomly selected patients who reached the
primary end point and provided an adequate blood sample
before randomization to the study. Each case was paired
with a control subject. Matching criteria were age, gender
and participating medical center. Controls (n  134) were
patients with CHD who remained free of any recurrent
coronary events and stroke throughout the follow-up period
and were alive at the end of study.
Laboratory procedures. Blood samples for measurement
of serum lipids, fibrinogen, blood chemistry and other
laboratory tests were collected at randomization (baseline)
and thereafter at regular intervals. All laboratory analyses
were performed in a single central laboratory using standard
automated procedures with commercial kits (17).
For the purpose of the present study, plasma samples that
had been taken at baseline from each study participant and
stored at 70°C were thawed and assayed for sICAM-1
using a commercial enzyme-linked immunosorbent assay kit
(R&D Systems, Minneapolis, Minnesota). A single labora-
tory technician, who was blinded to the case or control
status of each sample, performed all the tests.
Statistical analysis. Statistical analyses were done using the
SAS statistical software. To assess the significance of
differences between means of continuous variables, among
the matched pairs, we used the paired t test procedure. The
McNemar test for paired samples was used to assess
differences between rates.
We used logistic regression analyses conditioned on the
matching variables (age, gender and medical center) in order
to estimate the increase in relative odds of achieving the
primary end point, associated with each 100 ng/ml increase
in sICAM-1 concentration and with each 60 mg/dl increase
in fibrinogen concentration. Adjustment was made for
various baseline characteristics.
Conditional logistic regression (conditioned on the same
variables as above) was used to calculate the odds ratios
(OR) (and 95% confidence intervals [CI]) according to
quartiles of sICAM-1 serum level. Division to quartiles was
done according to sICAM-1 concentrations in a random
sample of BIP study participants who were free from any
cardiovascular events by the end of the study (n  310).
Similarly, we calculated ORs in quartiles of fibrinogen
serum level.
We adjusted for the use of study medication, serum lipid
concentrations at baseline and, finally, for multiple risk
factors for coronary events (diabetes mellitus, hypertension,
body mass index, New York Heart Association [NYHA]
functional class, history of MI, current smoking), fibrinogen
and white blood cell count.
In addition, conditional regression analyses were done to
calculate ORs of future coronary events in tertiles of
sICAM-1 concentration according to low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) concentrations (divided to tertiles).
RESULTS
Baseline characteristics. As expected from the study de-
sign and matching criteria, cases and controls were well
matched in terms of age and gender. Cases and controls
were fairly similar in terms of various coronary risk factors
(Table 1). Cases were in poorer functional class as assessed
by NYHA functional class, and they had a higher body mass
Abbreviations and Acronyms
BIP  Bezafibrate Infarction Prevention study
CHD  coronary heart disease
CI  confidence interval
HDL-C  high-density lipoprotein cholesterol
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarction
OR  odds ratio
sICAM-1  soluble intercellular adhesion molecule-1
VCAM-1  vascular cell adhesion molecule-1
Table 1. Baseline Characteristics of Cases and Controls on




(n  136) p Value
Age (SD) 61.4 (6) 61.6 (6) —
Men 129 (95%) 129 (95%) —
Bezafibrate treatment 62 (46%) 61 (45%) 0.56
Diabetes 13 (10%) 16 (12%) 0.55
Hypertension 43 (32%) 42 (31%) 0.89
Current smoking 12 (9%) 17 (13%) 0.32
Previous myocardial
infarction
106 (78%) 114 (84%) 0.25
Angina pectoris 80 (59%) 87 (64%) 0.44
Peripheral arterial disease 5 (4%) 11 (8%) 0.13
NYHA 2 25 (19%) 39 (29%)  0.05
DBP (mm Hg) 81 (8) 81 (9) 0.89
SBP (mm Hg) 133 (17) 136 (17) 0.18
BMI (kg/m2) 26 (3.2) 27.4 (3.3)  0.001
Cholesterol (mg/dl) 213 (16) 210 (17) 0.20
HDL cholesterol (mg/dl) 34 (6) 33 (6) 0.10
LDL cholesterol (mg/dl) 150 (16) 147 (16) 0.15
Triglycerides (mg/dl) 141 (51) 151 (45) 0.08
Fibrinogen (mg/dl) 348 (64) 365 (68) 0.048
Leukocytes/l (SD) 6,500 (1,400) 6,800 (1,800) 0.05
Continuous variables are given as mean (SD). Categorical variables are given as
number (%).
BMI  body mass index; DBP  diastolic blood pressure; HDL  high-density
lipoprotein; LDL  low-density lipoprotein; NYHA  New York Heart Associa-
tion; SBP  systolic blood pressure.
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index. Mean serum concentration of fibrinogen and total
white blood cell count were significantly higher in the cases
than in the control group, and serum triglycerides were
somewhat higher in cases than in controls (Table 1).
sICAM-1 level, distribution and correlates. Serum con-
centration of sICAM-1 was normally distributed in the
study sample, ranging from 19.4 ng/ml to 785.6 ng/ml, with
a mean level of 362.3 ng/ml (SD: 104.6 ng/ml) and a
median level of 345.5 ng/ml. Distribution of cases and
controls according to sICAM-1 concentration is shown in
Figure 1. The mean serum concentration of sICAM-1 was
significantly higher in cases (375 ng/ml [range: 19 ng/ml to
786 ng/ml]) than in the control group (350 ng/ml [range:
107 ng/ml to 707 ng/ml]).
Soluble ICAM-1 concentration correlated with triglyc-
eride concentration (r  0.28, p  0.01), fibrinogen level
(r  0.16, p  0.01) and white blood cell count (r  0.24,
p  0.01).
Occurrence of acute coronary events. Each elevation of
100 ng/ml (1 SD), in sICAM-1 concentration, was associ-
ated with a 1.27 (1.00 to 1.63) increased relative odds of
subsequent acute MI or sudden death (Table 2). Adjust-
ment for multiple confounders related to coronary risk,
including fibrinogen, or for white blood cell count did not
change the relative odds substantially (Table 2). For com-
parison, in a similar multivariate model, each 60 mg/dl
(1 SD) increase in fibrinogen concentration was associated
with a 1.19 (0.92 to 1.55) increased relative odds of
subsequent coronary events.
To explore the possibility that there is a threshold
concentration above which sICAM-1 levels are associated
with acute coronary events, we evaluated the risk for future
events according to sICAM-1 concentrations divided into
quartiles (see Methods section).
The unadjusted analysis of the matched pairs revealed a
significantly higher risk for subsequent MI or sudden death
in the highest quartile of sICAM-1 level than in the first
quartile (OR: 2.51, 95% CI: 1.21 to 5.45, p  0.02).
Adding the study medication to the model did not change
the result, nor did adjustment for serum lipids (Table 3).
Finally, a model that included multiple confounders
associated with coronary risk produced an OR of future MI
or sudden death of 2.31 (95% CI: 1.02 to 5.50, p 0.02) in
the highest quartile of sICAM-1 level (Table 3).
After adjustment for the inflammatory mediator fibrino-
gen, the relative odds of coronary events was 1.31 in the
second quartile of sICAM-1 concentration, 1.24 in the
third and 2.12 in the fourth (Table 3). Adjusting for white
blood cell count yielded relative odds of 1.43, 1.25 and 2.70
in the corresponding quartiles of sICAM-1 concentration
(Table 3).
For comparison, we evaluated future coronary risk ac-
cording to fibrinogen concentration divided to quartiles.
The crude relative odds of future coronary events were: 0.6
(0.25 to 1.29) in the second quartile of fibrinogen concen-
tration, 0.56 (0.27 to 1.13) in the third and 1.40 (0.73 to
2.75) in the fourth quartile (p for trend 0.18). Adjustment
for multiple confounders did not change these estimates.
Risk according to LDL-C and HDL-C level. The rela-
tive odds of future coronary events increased with increasing
sICAM-1 concentrations in the lowest and middle tertiles
of LDL-C concentrations but not in the highest tertile
(Table 4). Risk increased with increasing sICAM-1 con-
centration regardless of HDL-C levels (Table 4).
Time to event analysis. A previous report in healthy men
showed that the risk associated with elevated sICAM-1
concentration was noted after two years of follow-up (9). In
this analysis, the relative odds of sudden death or MI
associated with sICAM-1 levels above 394 ng/dl was 1.37
(0.39 to 5.06, p  0.62) in the first two years of follow-up,
and it increased to 3.5 (1.39 to 9.67, p  0.01) in events
occurring after two years.
DISCUSSION
Main findings. In this study, each 100 ng/ml increase in
sICAM-1 concentration was associated with a correspond-
ing 27% increase in the risk of future coronary events.
Coronary heart disease patients in the highest quartile of
sICAM-1 concentration were at particularly high risk, with
2.5 higher relative odds, compared with patients in the
lowest quartile. The risk remained elevated after adjustment
for traditional coronary risk factors and after adjustment for
fibrinogen and for total white blood cell count. Soluble
ICAM-1 was a stronger predictor than fibrinogen, which
was previously shown to be associated with cardiac mortality
and stroke (18–22).
Previous studies. In some cross-sectional studies, serum
levels of sICAM-1 were associated with atherosclerosis and
CHD (13,23), but not in others (14,15).
The predictive value of elevated sICAM-1 levels in
patients with stable CHD was only rarely investigated
prospectively. Soluble ICAM-1 levels were significantly
higher in patients with stable angina pectoris who developed
cardiac events than in patients who did not develop any
events during follow-up (16). However, this was a small
study with only seven patients in the events group, and it
was therefore not feasible to adjust for any possible con-
founders (16). To the best of our knowledge, our study is
the first one to evaluate, both prospectively and over a long
follow-up period, the risk associated with elevated
sICAM-1 levels in patients with symptomatic but stable
CHD.
By contrast with our study, in a recent community study,
sICAM-1 was not independently associated with future
development of CHD (12). However, it should be noted
that in Malik’s study only 25% of the study participants had
CHD at baseline, whereas in our study all the patients had
proven CHD. In addition, sera that were tested for
sICAM-1 were kept at 20°C in Malik’s study, compared
with 70°C in the present study (this could affect
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sICAM-1 concentrations differently over time). Malik et al.
(12) evaluated the top tertile of sICAM-1 concentration (vs.
lowest tertile), whereas in our study, we compared the upper
quartile with the lowest quartile.
In the Atherosclerosis Risk in Communities (ARIC)
study and in the Physician’s Health study, elevated baseline
levels of sICAM-1 predicted future development of carotid
artery atherosclerosis (11) and CHD (9,11) in healthy
persons, even after adjustment for inflammatory mediators
(11), including C-reactive protein, fibrinogen (9) and other
adhesion molecules (11). In addition, sICAM-1 levels were
significantly higher in healthy women who subsequently
developed CHD than in women who did not develop CHD
(7).
Serum levels of sICAM-1, vascular cell adhesion
molecule-1 (VCAM-1) and E-selectin increase during
acute coronary events (24–29) and remain elevated for six
months, but not thereafter (26). The BIP study included
only patients whose coronary event had occurred six months
or more prior to that study. The sample for the present
study was selected from the BIP study, therefore eliminating
any possible confounding related to increased sICAM-1
concentration after an acute coronary event.
Pathophysiology. Soluble ICAM-1, a member of the im-
munoglobulin super family, plays an important role in the
adhesion of mononuclear cells to endothelial cells, promot-
ing progression of atherosclerotic plaques and transforma-
tion of the stable plaque into an unstable plaque through
invasion of circulating monocytes into the atheroma (1,4,5).
Thus, elevated sICAM-1 levels in patients with CHD may
indicate not only a tendency toward enhanced progression
of the atherosclerotic process but also an inherent propensity
Figure 1. Distribution of cases (black bars) and controls (white bars) according to soluble intercellular adhesion molecule-1(sICAM-1) concentrations.
Table 2. Relative Odds of Coronary Events in CHD Patients
With 100 ng/ml Increase in sICAM-1 Concentration
Odds Ratio
(95% CI)
Unadjusted analysis 1.27 (1.00–1.63)
Study medication* 1.27 (1.00–1.63)
Lipids† 1.25 (0.96–1.66)
Multivariate analysis‡ 1.27 (0.97–1.70)
 Fibrinogen§ 1.27 (0.95–1.72)
 White blood cell count 1.26 (0.95–1.72)
All analyses are matched on age, gender and participating medical center.
*Adjusted for the use of bezafibrate; †adjusted for the use of bezafibrate, HDL
cholesterol, LDL cholesterol and triglycerides; ‡adjusted for diabetes mellitus,
previous myocardial infarction, hypertension, smoking, use of bezafibrate, body mass
index and NYHA class; §adding fibrinogen concentration to the multivariate model;
adding white blood cell count to the multivariate model.
CHD  coronary heart disease; HDL  high-density lipoprotein; LDL 
low-density lipoprotein; NYHA  New York Heart Association; sICAM-1 
soluble intercellular adhesion molecule-1.
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toward plaque instability and rupture, hence the increased
risk of recurrent MI and sudden death over time in patients
with elevated sICAM-1.
The results of the present study add to the insight gained
previously from studies in healthy persons, which have
shown the importance of cytokines and circulating adhesion
molecules as predictors of future atherosclerosis and CHD
(7–11). More recently, VCAM-1 was found to predict
recurrent coronary events in patients with unstable coronary
syndromes (29). In the present study, on-going inflamma-
tory activity, marked by elevated sICAM-1 concentration,
predicted future coronary events in patients with chronic
stable CHD.
Study limitations. This study relied on a single measure-
ment of sICAM-1 in sera that were kept frozen for 10 years.
Others have used similar methodology and laboratory meth-
ods to investigate the role of adhesion molecules and
cytokines in CHD (7–12).
Studies such as ours cannot provide data on the origin of
circulating sICAM-1. Whether from the coronary circula-
tion or from systemic inflammation, the evidence for the
strong association between inflammatory activity and sub-
sequent risk for coronary events is nevertheless substantial.
We did not measure C-reactive protein or other inflam-
matory mediators. And we cannot compare their predictive
value to that of sICAM-1. However, this kind of compar-
ison was beyond the scope of the present study, which
aimed to evaluate the role of sICAM-1 as a predictor of
future acute coronary events in patients with stable CHD.
Despite these limitations, our study sample provides an
excellent opportunity to assess the relationship between
sICAM-1 and long-term (6.2-year) risk for acute coronary
events in CHD patients. Our patients were under close
monitoring for recurrent events, which were confirmed by
an independent critical events committee.
Conclusions. Patients with CHD with elevated sICAM-1
levels were at increased risk for future MI and sudden death.
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APPENDIX
A complete list of Bezafibrate Infarction Prevention (BIP)
study investigators and participating medical centers has
been previously published (17).
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